The Journal of Korean Obstetrics and Gynecology (대한한방부인과학회지)

The Society of Korean Medicine Obstetrics and Gynecology (대한한방부인과학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Changbudodam-tang on Obesity-induced Rats

창부도담탕이 비만 유도 흰쥐에 미치는 영향

  • Kim, Soo-Hyeon (Dept. of Korean Gynecology and Obstetrics, College of Korean Medicine, Dong-Shin University) ;
  • Lee, Eun-Kyu (Dept. of Korean Gynecology and Obstetrics, College of Korean Medicine, Dong-Shin University) ;
  • Choe, Yoo-Jin (Dept. of Korean Gynecology and Obstetrics, College of Korean Medicine, Dong-Shin University) ;
  • Jo, Seong-Hui (Dept. of Korean Gynecology and Obstetrics, College of Korean Medicine, Dong-Shin University) ;
  • Yang, Seung-Jeong (Dept. of Korean Gynecology and Obstetrics, College of Korean Medicine, Dong-Shin University)
  • 김수현 (동신대학교 한의과대학 한방부인과교실) ;
  • 이은규 (동신대학교 한의과대학 한방부인과교실) ;
  • 최유진 (동신대학교 한의과대학 한방부인과교실) ;
  • 조성희 (동신대학교 한의과대학 한방부인과교실) ;
  • 양승정 (동신대학교 한의과대학 한방부인과교실)
  • Received : 2021.01.13
  • Accepted : 2021.02.26
  • Published : 2021.02.26
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: This study was designed to evaluate the efficacy of Changbudodam-tang on obesity by using high-fat diet rats. Methods: Rats were divided into five groups. Normal group: Normal diet, Control group: High-fat diet, Positive control group: High-fat diet+Dietamin 4 mg/kg/day, Changbudodam-tang-Low group: High-fat diet+Changbudodam-tang 250 mg/kg/day, Changbudodam-tang-High group: High-fat diet+Changbudodam-tang 500 mg/kg/day. Weight, food intake were measured every week. After 7 weeks, total cholesterol, high density lipoprotein-cholesterol, low density lipoprotein-cholesterol, Triglyceride, free fatty acid, aspartate aminotransferase, alanine aminotransferase, complete blood count were measured and messenger ribonucleic acid expression of adiponectin, peroxisome proliferator-activated receptor-γ, leptin were observed using Reverse transcription polymerase chain reaction of liver cells. Results: There was no difference in food intake between groups. Body weight tended to decrease compared with the Control group, but it wasn't statistically meaningfull. The total cholesterol, low density lipoprotein-cholesterol, Triglyceride, free fatty acid tended to decrease compared with the Control group. High density lipoprotein-cholesterol tended to decrease compared with the Control group, but it wasn't statistically meaningfull. White blood cell, red blood cell, hemoglobin, platelet, aspartate aminotransferase, alanine aminotransferase were not affected by Changbudodam-tang. The messenger ribonucleic acid expression of Adiponectin, peroxisome proliferator-activated receptor-γ, leptin, which are involved in the differentiation of adipocytes, was decreased compared with the Control group. Conclusions: Based on the results above, it is suggested that Changbudodam-tang can be applied to improving serum lipid levels in obese patients caused by high fat diets.

Keywords

References

  1. The Society of Korean Medicine Obstetrics & Gynecology. Oriental Obstetrics & Gynecology (Vol 2). 1st ed. Seoul: Euiseongdang. 2012:295, 298, 302, 303.
  2. Hong EK. Pathophysiology of Adult Obesity and Related-disease. Korean Clinical Diabetes. 2008;9(3):148-52. https://doi.org/10.4093/kcd.2008.9.3.148
  3. Sullivan PW, Ghushchyan VH, Ben-Joseph R. The impact of obesity on diabetes, hyperlipidemia and hypertension in the United States. Qual Life Res. 2008; 17(8):1063-71. https://doi.org/10.1007/s11136-008-9385-7
  4. Korean National Health and Nutrition Survey. The prevalence of obesity. [cited Dec 17, 2020]. Available from:URL: https://search.naver.com/search.naver?where=nexearch&sm=top_hty&fbm=1&ie=utf8&query=%EB%B9%84%EB%A7%8C+%EC%9C%A0%EB%B3%91%EB%A5%A0
  5. National Health Insurance Service. 11.4679 trillion won in social losses from obesity. [cited Dec 17, 2020]. Available from:URL:https://www.nhis.or.kr/nhis/together/wbhaea01600m01.do?mode=view&articleNo=127965
  6. Kim CH. Pharmacologic Therapy for Obesity. Diabetes and Metabolism Journal. 2008;9(3):173-7.
  7. Connolly HM, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581-8. https://doi.org/10.1056/NEJM199708283370901
  8. James WP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-22. https://doi.org/10.1056/NEJMoa1003114
  9. Chae IS. Sinpyeon Jeoncheongjunamyeokwa Seopcheonsayeokwa. Seoul:Daeseong. 1992:192, 193, 215, 227.
  10. Hwang DY. Jeungmaek Bangyakhappyeon Jeungbobang. Seoul:Namsandang. 1996 :330-1.
  11. Yang SJ, et al. Effects of Changbudodam-tang on the Polycystic Ovaries Induced by Estradiol Valerate in Rats. J Korean Obstet Gynecol. 2002;15(2): 1-11.
  12. Song JM, Lee IS. Experimental Study for the Effect of Cheonghaechangsa-hwan and Changbudodam-hwan. J Korean Obstet Gynecol. 1997;10(1):151-61.
  13. Kang BH, et al. Effects of Changbudodam-hwan on the ovulation in rats. The Journal of Traditional Korean Medicine. 2003;13(1):15-26.
  14. Korean Society For The Study Of Obesity. Clinical obesity. Seoul:Korea Medical Book Publishing Company. 2001:19-29.
  15. Korean Endocrine Society, Korean Society For The Study of Obesity. Management of Obesity, 2010 Recommendation. Endocrinology and metabolism. 2010;25(4):301-4. https://doi.org/10.3803/EnM.2010.25.4.301
  16. Ministry of Foreign Affairs. Heavy Burden of Obesity: The Economics of Prevention. [cited Dec 27, 2020]. Available from:URL:https://overseas.mofa.go.kr/oecd-ko/brd/m_20807/view.do?seq=111
  17. Lee HK. Obesity and Its Associated Diseases. Journal of Obesity & Metabolic Syndrome. 1992;1(1):34-9.
  18. Hensrud DD. Pharmacotherapy for obesity. Med Clin North Am. 2000;84(2):463-76. https://doi.org/10.1016/s0025-7125(05)70231-5
  19. Kim MK, et al. 2014 clinical practice guidelines for overweight and obesity in Korea. Endocrinology and metabolism. 2014;29(4):405-14. https://doi.org/10.3803/enm.2014.29.4.405
  20. Vetter ML, et al. Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol. 2010;6(10): 578-88. https://doi.org/10.1038/nrendo.2010.121
  21. Seo MH, et al. Corrigendum: 2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea. J Obes Metab Syndr. 2019;28(1):40-5. https://doi.org/10.7570/jomes.2019.28.1.40
  22. Shin HJ. Domestic adverse event and signal detection of anti-obesity medicines using KIDS-KD. Department of Pharmacy, Graduate School, Sungkyunkwan University. 2020.
  23. Korea Pharmaceutical Information Center. Medication Details. [cited Dec 17, 2020]. Available from:URL:http://www.health.kr/searchDrug/result_drug.asp?drug_cd=A11AOOOOO6098
  24. Lee CJ, Kim MJ, An SJ. Current treatments on obesity. Korean Journal of Health Promotion. 2019;19(4):171-85. https://doi.org/10.15384/kjhp.2019.19.4.171
  25. Kim DH, Lee JH. Hwangjenaekyeongsomun. 1st ed. Seoul:Euiseongdang. 2002:652, 974.
  26. The Society of Korean Medicine Rehabilitation. Korean Rehabilitation Medicine. 4 th ed. Paju:Koonja. 2015:298-317.
  27. Jeong JW. Trend research of the human body-oriented obesity studies on oriental medicine. J Korean Med Rehab. 2016; 26(1):49-61. https://doi.org/10.18325/jkmr.2016.26.1.49
  28. Sin MK. Imsangbonchohak. Seoul: Samkwanginswaesa. 2000:172-4, 180-2, 469-71, 477-8, 483, 587-8, 649-52, 744-7, 819-21.
  29. Ha KS. Silyongbukwabangjehak. Bukkyeong: Inminwisaengchulpansa. 1997:272-3.
  30. Cnop M, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoprotein; evidence for independent roles of age and sex. Diabetologia. 2003;46(4):459-69. https://doi.org/10.1007/s00125-003-1074-z
  31. Weiss R, et al. Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation. J Clin Endocricnol Metab. 2003;88(5):2014-22. https://doi.org/10.1210/jc.2002-021711
  32. Hotta K, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 deabetic patients. Arterioscler. Thromb Vasc Biol. 2000;20(6):1595-604. https://doi.org/10.1161/01.ATV.20.6.1595
  33. Yang WS, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J ClinEndocrinol Metab. 2001;86(8):3815-24. https://doi.org/10.1210/jcem.86.8.7741
  34. Rosen ED, et al. PPAR is required for differentiation of adipose tissue in vitro. Mol cell. 1999;4(4):611-7. https://doi.org/10.1016/S1097-2765(00)80211-7
  35. Maffei M, et al. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995;1(11):1155-216. https://doi.org/10.1038/nm1195-1155
  36. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395(6704):763-833. https://doi.org/10.1038/27376